Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the plenary session
https://www.timm2023.org/monday-23-october-2023/
I did not realize the ingredients but this article is interesting regarding utility of nasal sprays for covid
https://www.webmd.com/covid/what-to-know-about-experimental-nasal-sprays-for-covid
The swab including brilacidin might slso make a great prophylactic as previously discussed for nasal sprays using other agents
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313533/
What ever happened to the gm negative drug ctix 1807 that per this article
https://www.globenewswire.com/news-release/2014/12/22/955426/0/en/Cellceutix-Reports-Positive-Results-of-Brilacidin-in-Microbiological-Intent-to-Treat-Population-in-Phase-2b-ABSSSI-Trial-Additional-Pharmacokinetic-Information-to-Be-Submitted.html
Was to have been analyzed as pare of a half million dollar grant to Fox Chase to analyze our platform technology
Biotech Showcase - Innovation Pharmaceuticals https://daniel-pizza-pl53.squarespace.com/s/Cellceutix_Mon_Biotech-Showcase_20161.pdf
The early bird catches the worm. We better watch out or others will be the first to market a Peptide based antiinfective.
Check out this story: Peptide spray kills bacteria in wounds without using antibiotics https://flip.it/vyLkoX from Flipboard.
This is a quote from temple news article below
“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987.
https://news.temple.edu/news/2021-12-14/michael-l-klein-wins-prestigious-john-scott-award
Brilacidin has previously been shown to be a good antibacterial against MRSA /gm positive bacteria as well in the eye
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742993/
Quote from an article about another drug https://flip.it/juGfsM "as they envision a nasal spray or drops that can be used to prevent or treat coronavirus and influenza infections, in seasonal and pandemic situations."
Actual title if last article I posted
Activity of Antimicrobial Peptide Mimetics in the Oral Cavity: I. Activity Against Biofilms of Candida albicans
Activity of Antimicrobial Peptide Mimetics in the Oral Cavity
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992321/
When Cellceutix now Innovation pharmaceuticals acquired Polymedix it acquired many compounds, some with more antifungal specificity them Brilacidin some with more gram neg specificity then Brilacidin.
When Innovation pharmaceuticals sold the rights of its antifungal technology to Fox Chase did it include the Brilacidin in this sale as an antifungal or did it just include other defensin mimetic antifungals in their library of compounds?
The company,Huateng Pharma,states it supplies an intermediate for Brilacidin synthesis and has the capacity for rapid scale up and "capacity to produce up to tons” in an article from April 2021- also discussing HDP-mimetics
https://en.huatengsci.com/article/302.html
TP53 is the most commonly mutated gene in All cancers-35% of all cancers per this recent article below. https://www.nature.com/articles/s41467-021-26213-y
Once we have money (which will hopefully be in our coffers shortly as we likely have an amazing treatment for Covid 19)we can work on treating more than 1/3 of all cancers by developing Kevetrin.
We can also use this money on all the other GI and antiinflammatory(oral mucositis and likely other conditiins) indications of our wonder drug Brilacidin.These 2 drugs could potentially be the seed that grows into a huge company-, a tree with many branches whose leaves can be pharmaceutically compounded to treat many medical conditions.
We expext good news about Covid shortly but we should not forget kevetrin .Most commonly mutated gene in all cancers is p53 per recent article in Nature.
https://www.nature.com/articles/s41467-021-26213-y
In 2015 you said"My WAG is $20 within 30 trading days after announcement of the first partner/license. However broad or regional the agreement, it will be a billion dollar deal and will de-risk all other trials thr
ough fully funding everything else in the pipeline. That alone is worth adding another $10 a share. Then there is the added value of uplisting; $50 by 2017 is probably too low. "
Why the current pessimism on share price potential? The current sticker price does not even come close to reflecting the value of a potential panantiviral and at the least a potential covid treatment, new MRSA antibiotic with great antibiotic potential and antibiofilm potential . An anti inflammatory with GI and radiation induced oral mucositis potential. We also have kevetrin a drug that can likely modulate p53 in a multitude of cancers and could a major new chemotherapeutic agent. In 2015 price per share was a lot higher but likewise even then price per share did not reflect value.
Here is another article on
Peptoids which they they indicate has "years of development and commercialization "before use. The peptoid concept appears very similar to Brilacidin, a defensin mimetic , and this article likewise calls peptoids a biomimetic.
https://www.newswise.com/coronavirus/what-if-we-could-give-viruses-a-one-two-punch
Article on use of defensin as antineoplastic
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537071/
Detergent-like protein kills bacteria in human cells
Sounds like Brilacidin disruption of lipid membrane in bacteria
https://flip.it/P_f0mN
This is an interesting article on antiviral peptides with mention of Brilacidin. I do not know if this article was already mentioned.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156787/#__ffn_sectitle
Pulmonary fibrosis is involved in the morbidity and mortality of many diseases besides covid. If brilacidin inhibits this process by inhibiting fibroblast proliferation it could potentially have utility in many other diseases
https://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/symptoms-causes/syc-20353690
Covid 19 may play a role in development of fibroblast mediated pulmonary fibrosis
https://thorax.bmj.com/content/early/2021/05/13/thoraxjnl-2021-217031
https://pubmed.ncbi.nlm.nih.gov/34028807/
Given that brilacidin inhibits fibroblasts could this indicate a role of Brilacidin in preventing long term lung toxicity
Others are working on similar concept drugs
https://www.newswise.com/coronavirus/what-if-we-could-give-viruses-a-one-two-punch
Sounding familiar -but we already have a peptidomimetic with likely broad spectrum capabilities to becknown to the world shortly
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention
This article above which I quote below contains recommendations about conduct and design of clinical trials on COVID from the FDA and explains why interim data analysis for efficacy will likely not be performed as “releasing interim results could have ramifications on the integrity of the ongoing trial and the ability to collect reliable and interpretable data needed to support regulatory decision-making.”
One can also see that our trial design appears to be following these recommendations for trial design and analysis to a T, hopefully facilitating EUA upon release of great results.
I do not know if anyone else posted this good summary of Brilacidin as an antviral
https://www.precisionvaccinations.com/vaccines/brilacidin-covid-19-therapeutic
Dr. Narayanan states in this video
I am not sure if this was mentioned previously.The attached is a link to a You Tube lecture from the Mason Science Series from Dr. Aarthi Narayanan in which she shares her research about COVID including Brilacidin.
Who is Warren Weston? He is listed as working as a consultant for Innovation Pharm on the preprint server article
I cannot edit a post after sending it. How do I edit a post or delete it?
I wish I could convince my wife to agree to let me accumulate a substantial amount more in this price range. She will not as I had good deal if money invested prior to Covid at a much higher price per share and am still way behind.
Artucle "Radiotherapy for oral cancer decreases theccutaneous expression of host defense peptides"- perhaps giving more reason that B OM might be beneficial for treating radiotherapy induced mucositis.
https://www.researchgate.net/publication/301758622_Radiotherapy_for_oral_cancer_decreases_the_cutaneous_expression_of_host_defence_peptides
Defensins and cancer a few articles of relevance:
1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537071/
2) https://www.sciencedirect.com/science/article/abs/pii/S1874391909000098
3) https://www.spandidos-publications.com/ijo/45/3/1059?text=fulltext
4)
https://cancerres.aacrjournals.org/content/64/7_Supplement/619.2
https://www.frontiersin.org/articles/10.3389/fonc.2019.00341/full
I subsequently did a little more of a search and found a list of patents acquired from polymedix
https://www.sec.gov/Archives/edgar/data/1355250/000147793214002418/ctix_ex1037.htm
It includes as quoted from above:
"This application claims pharmaceutical compositions and uses for facially amphiphilic polymers, oligomers and small molecules that are polyamides, polyesters, polyurea, polyurethane, polycarbonate, or polyphenylene, compounds. Uses include method of treatment (systemic and topical) as antimicrobial agents against bacteria, fungi and viruses and as an antidote to heparin and LMWH. Also, composition of matter claims are expanded
This is a more direct link to the article:
https://www.newyorker.com/science/medical-dispatch/the-state-of-the-fight-against-covid-19
This is another link to the article from the New Yorker Magazine:
https://www.newyorker.com/science/medical-dispatch/the-state-of-the-fight-against-covid-19